Results 41 to 50 of about 23,170 (228)

Table_5_Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.xlsx [PDF]

, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778), Marieke Griffioen (119817), Dyantha I. van der Lee (3115227), Szymon M. Kielbasa (8722956), Margot J. Pont (3115230), M. Willy Honders (8722947), Kyra J. Fuchs (8722944), Ramin Monajemi (6874238), Edith D. van der Meijden (8722950), Alwin E. Adriaans (8722953), Cornelis A. M. van Bergen (5657533), Peter A. C. ’t Hoen (8722959)   +11 more
core   +1 more source

Table_6_Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.xlsx [PDF]

, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778), Marieke Griffioen (119817), Dyantha I. van der Lee (3115227), Szymon M. Kielbasa (8722956), Margot J. Pont (3115230), M. Willy Honders (8722947), Kyra J. Fuchs (8722944), Ramin Monajemi (6874238), Edith D. van der Meijden (8722950), Alwin E. Adriaans (8722953), Cornelis A. M. van Bergen (5657533), Peter A. C. ’t Hoen (8722959)   +11 more
core   +1 more source

Table_1_Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.xlsx [PDF]

, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778), Marieke Griffioen (119817), Dyantha I. van der Lee (3115227), Szymon M. Kielbasa (8722956), Margot J. Pont (3115230), M. Willy Honders (8722947), Kyra J. Fuchs (8722944), Ramin Monajemi (6874238), Edith D. van der Meijden (8722950), Alwin E. Adriaans (8722953), Cornelis A. M. van Bergen (5657533), Peter A. C. ’t Hoen (8722959)   +11 more
core   +1 more source

Consequence of Histoincompatibility beyond GvH-Reaction in Cytomegalovirus Disease Associated with Allogeneic Hematopoietic Cell Transplantation: Change of Paradigm

Viruses, 2021
Hematopoietic cell (HC) transplantation (HCT) is the last resort to cure hematopoietic malignancies that are refractory to standard therapies. Hematoablative treatment aims at wiping out tumor cells as completely as possible to avoid leukemia/lymphoma ...
Matthias J. Reddehase, Rafaela Holtappels, Niels A. W. Lemmermann   +2 more
doaj   +1 more source

Image_1_Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.jpg [PDF]

, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778), Marieke Griffioen (119817), Dyantha I. van der Lee (3115227), Szymon M. Kielbasa (8722956), Margot J. Pont (3115230), M. Willy Honders (8722947), Kyra J. Fuchs (8722944), Ramin Monajemi (6874238), Edith D. van der Meijden (8722950), Alwin E. Adriaans (8722953), Cornelis A. M. van Bergen (5657533), Peter A. C. ’t Hoen (8722959)   +11 more
core   +1 more source

Table_4_Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.xlsx [PDF]

, 2020
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778), Marieke Griffioen (119817), Dyantha I. van der Lee (3115227), Szymon M. Kielbasa (8722956), Margot J. Pont (3115230), M. Willy Honders (8722947), Kyra J. Fuchs (8722944), Ramin Monajemi (6874238), Edith D. van der Meijden (8722950), Alwin E. Adriaans (8722953), Cornelis A. M. van Bergen (5657533), Peter A. C. ’t Hoen (8722959)   +11 more
core   +1 more source

Expanding the immunotherapeutic potential of minor histocompatibility antigens. [PDF]

J Clin Invest, 2005
Minor histocompatibility antigens (mHAgs) selectively expressed by cells or cell subsets of the hematopoietic system are targets of the T cell-mediated graft-versus-leukemia response that develops following allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies.
Spierings E, Goulmy E.
europepmc   +4 more sources

A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform

Frontiers in Immunology, 2021
The bone marrow transplantation (BMT) between haplo-identical combinations (haploBMT) could cause unacceptable bone marrow graft rejection and graft-versus-host disease (GVHD).
Hisanori Mayumi
doaj   +1 more source

Role of Minor Histocompatibility Antigens in Renal Transplantation [PDF]

American Journal of Transplantation, 2008
In hematopoietic stem cell transplantation (HSCT), disparities between recipients and donors for minor histocompatibility antigens (mHags) have been shown to be related to graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects. We investigated the effect of mHag mismatches on kidney allograft survival. Out of 33 785 kidney transplants
A, Heinold, G, Opelz, S, Scherer, A, Ruhenstroth, G, Laux, B, Doehler, T H, Tran   +6 more
openaire   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source